Eterna Therapeutics Inc. (ERNA)
0.17
-0.06 (-24.88%)
At close: Mar 28, 2025, 3:59 PM
0.19
9.07%
Pre-market: Mar 31, 2025, 04:06 AM EDT
-24.88% (1D)
| Bid | 0.14 |
| Market Cap | 8.89M |
| Revenue (ttm) | 2.23M |
| Net Income (ttm) | -170.51M |
| EPS (ttm) | -3.21 |
| PE Ratio (ttm) | -0.05 |
| Forward PE | -0.05 |
| Analyst | n/a |
| Ask | 0.19 |
| Volume | 889,055 |
| Avg. Volume (20D) | 10,738,126 |
| Open | 0.22 |
| Previous Close | 0.23 |
| Day's Range | 0.16 - 0.24 |
| 52-Week Range | 0.16 - 2.63 |
| Beta | 7.33 |
About ERNA
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics,...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 29, 1991
Employees 6
Stock Exchange NASDAQ
Ticker Symbol ERNA
Website https://www.brooklynitx.com
2 months ago
+48.22%
Eterna Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
